
CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating (NASDAQ:CTIC)
This article was written by Follow We focus on small and mid-cap healthcare and technology companies. We publish short and long ideas.Disclaimer: Biotechvalley Insights (BTVI) is not a registered investment advisor, and articles are not […]